Since immunologic studies of patient samples and zebrafish models in VEXAS syndrome demonstrated upregulation of multiple cytokine signatures including TNF, IL-6 and IFN-γ (Beck et al., 2020), a broad therapeutic approach could be beneficial rather than the specific blockade of single cytokines. The gene discussed is TNF; the disease is VEXAS syndrome.